BiotechTube
Noven Pharmaceuticals

Noven Pharmaceuticals

Miami, United States· Est.
noven.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Noven Pharmaceuticals is a U.S.-based, commercial-stage specialty pharma company with a core competency in transdermal patch technology. Founded in 1989, the company has a portfolio of marketed products for ADHD, schizophrenia, and menopausal hormone therapy, leveraging its fully integrated capabilities from R&D to sales. As a wholly-owned subsidiary of Hisamitsu, Noven benefits from deep transdermal expertise and manufacturing scale while focusing on niche CNS and women's health markets. Its strategy combines internal development with strategic partnerships to expand its product offerings.

Mental HealthWomen's Health

Technology Platform

Industry-leading transdermal drug delivery expertise for developing, manufacturing, and commercializing prescription patch systems.

Opportunities

Growing demand for non-oral, compliant drug delivery systems in mental health and chronic disease management presents a significant opportunity.
Leveraging the parent company's global R&D and manufacturing scale can fuel the U.S.
pipeline with new transdermal candidates.
The established commercial infrastructure allows for efficient launch and lifecycle management of new products.

Risk Factors

Revenue is dependent on a small number of marketed products, facing intense competition in both ADHD and schizophrenia markets.
As a subsidiary, strategic direction is ultimately set by the parent company, Hisamitsu.
Long-term growth requires continuous pipeline innovation or successful in-licensing to offset patent expiries.

Competitive Landscape

Noven competes in niche segments against large pharmaceutical companies with broad CNS portfolios (e.g., Johnson & Johnson, Otsuka, AbbVie) and other specialty pharma players. In women's health, it competes with other MHT manufacturers. Its primary competitive advantage is its focused transdermal expertise and integrated manufacturing, differentiating it on drug delivery technology rather than novel molecular entities.

More companies in Small Molecule Drugs →More companies in United States →